Editorially Independent content supported with advertising by Genentech
Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD
Show Description +
In an era concerned with safety, how do retina specialists balance their desire to access more durable therapies with the realities of safety? Priya Sharma Vakharia, MD; Joseph M. Coney, MD, and Jordan M. Graff, MD, provide insights on how high-dose aflibercept (Eylea, Regeneron) fits into the treatment landscape, what levels of drug-related risk they tolerate in patients with wet AMD and DME, and how the latest real-world positive safety data for faricimab (Vabysmo, Genentech/Roche) inform their treatment decisions.
Posted: 10/03/2023
Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD
In an era concerned with safety, how do retina specialists balance their desire to access more durable therapies with the realities of safety? Priya Sharma Vakharia, MD; Joseph M. Coney, MD, and Jordan M. Graff, MD, provide insights on how high-dose aflibercept (Eylea, Regeneron) fits into the treatment landscape, what levels of drug-related risk they tolerate in patients with wet AMD and DME, and how the latest real-world positive safety data for faricimab (Vabysmo, Genentech/Roche) inform their treatment decisions.
Posted: 10/03/2023
Please log in to leave a comment.